Document ID: chunk:federal_register_of_legislation:F2020L00201:reg:8:p2
Version: federal_register_of_legislation:F2020L00201
Segment Type: reg
Provision Reference: reg 8 (pt 2/2)
Character Range: 6136–8921

affected site at the time of the clinical onset of osteonecrosis;
(15)      having glucocorticoid therapy as specified, before the clinical onset of osteonecrosis, and where the glucocorticoid therapy as specified has ceased or decreased, the last dose of the therapy was received within the five years before the clinical onset of osteonecrosis;
Note: glucocorticoid therapy as specified is defined in the Schedule 1 - Dictionary.
(16)      taking bevacizumab, denosumab or testosterone within the 30 days before the clinical onset of osteonecrosis;
(17)      having a solid organ transplant, stem cell transplant or bone marrow transplant before the clinical onset of osteonecrosis;
(18)      undergoing a course of therapeutic radiation for cancer, where the affected site was in the field of radiation, before the clinical onset of osteonecrosis;
(19)      having internal deposition of radium-224, radium-226, or radium-228 before the clinical onset of osteonecrosis;
(20)      having decompression sickness within the two years before the clinical onset of osteonecrosis;
(21)      experiencing hyperbaric exposure as specified, within the two years before the clinical onset of osteonecrosis;
Note: hyperbaric exposure as specified is defined in the Schedule 1- Dictionary.
(22)      being pregnant at the time of the clinical onset of osteonecrosis;
(23)      undergoing childbirth within the one year before the clinical onset of osteonecrosis;
(24)      for osteonecrosis of the jaw only:
(a)          having diabetes mellitus at the time of the clinical onset of osteonecrosis;
(b)          having periodontitis, periodontal abscess or dental pulp and apical disease within the three months before the clinical onset of osteonecrosis;
(c)          having syphilitic palatine gumma at the time of the clinical onset of osteonecrosis; or
(d)          having acute herpes zoster involving the trigeminal nerve within the six months before the clinical onset of osteonecrosis;
(e)          having substance use disorder, involving cocaine, at the time of the clinical onset of osteonecrosis;
(f)           being treated with an osteoclast inhibitor for at least six months before the clinical onset of osteonecrosis, where the last dose of the drug was taken within the two years before the clinical onset of osteonecrosis; or
Note: osteoclast inhibitor is defined in the Schedule 1 - Dictionary.
(g)          being treated with an antiangiogenic agent for at least six months before the clinical onset of osteonecrosis, where the last dose of the drug was taken within the two years before the clinical onset of osteonecrosis;
Note: antiangiogenic agent is defined in the Schedule 1 - Dictionary.
(25)      inability to obtain appropriate clinical management for osteonecrosis.